Leading pharmaceutical M&A deal value in China 2019, by acquirer
The American multinational biotechnology company Amgen Inc. spent about 2.8 billion U.S. dollars to acquire the biopharmaceutical company BeiGene Ltd in October 2019 - the largest M&A investment deal made in China's pharmaceutical sector that year. It was the only foreign investment among the top ten M&A deals.